Exsurgo’s Mindpower Newsletter – November 2022

Hi all, We are thrilled to share that our final trialist has completed the Active Neurofeedback Treatment phase of the New Zealand Axon trial in partnership with Auckland University of Technology (AUT) and Waitematā District Health Board (WDHB). As a random Controlled Clinical Trial, it is considered the ‘gold standard’ of clinical trials. The trial data and improvement in patient outcomes is extremely encouraging and we look forward to releasing the clinical results in the coming months. In other news, I recently returned from an exciting trip to secure ongoing funding to roll out Axon commercially, with a stop off at the GITEX Expo in Dubai en route to the U.S. GITEX was an incredibly rewarding experience, where I met with industry leaders in the technology sector, showcased our Axon headset on the global stage and tested out exciting new technology. We remain focused on our ongoing research projects and additional clinical trials to demonstrate the multi-use functionality and efficacy of our product offering. All the best, Richard

Previous Article

Confessions of a health tech entrepreneur

This article first appeared in NZBusiness Magazine. Richard Little is an invento…


Next Article

When a game is more than play

How gamification can support treatment for chronic pain and other neurological c…